The Special Populations Networks (SPN) project is widely regarded as perhaps the most successful in the history of the National Cancer Institute (NCI) at performing cancer awareness, research, and training activities within minority and underserved communities throughout the United States and its territories. Key to that success is the trust established among the community, its researchers and the NCI. Composed of 18 separate grant awards, the SPN project was implemented in April 2000 to integrate the communities' need for cancer information with the NCI's need to increase cancer awareness, perform new research, and train minority junior investigators for research in populations with a disproportionate burden of cancer. To date, the 18 networks have conducted more than 1,000 awareness events, trained more than 2,000 community health aides, won 135 grants to support pilot research projects, published 130 peer-reviewed papers, and raised another $20 million to support SPN activities. Successful implementation of the SPN project required the principal investigators to establish and maintain close working relationships with key community leaders and organizations in cooperation with NCI.
Download full-text PDF |
Source |
---|
Asia Pac J Clin Oncol
January 2025
LifeStrands Genomics Australia, Mount Waverley, Victoria, Australia.
Some patients with metastatic castration-resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2. Tumors with BRCA mutations exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with BRCA mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC.
View Article and Find Full Text PDFCancer Control
January 2025
Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh, Saudi Arabia.
Introduction: Cancer patients often face challenges in managing their disease, particularly with regard to contraindications related to medications, foods, and physical activity, which can negatively affect treatment outcomes. This study aimed to evaluate cancer patients' awareness of these contraindications and to explore the influence of sociodemographic factors, support systems, comorbidities, and medication use on their knowledge.
Methods: A cross-sectional prospective study was conducted with 125 cancer patients in Saudi Arabia between December 2022 and February 2023.
BMC Res Notes
January 2025
Non-Communicable Diseases Research Center, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Thyroid cancer is one of the most common cancers of the endocrine system. The incidence of this cancer has increased in many countries. Many cases of thyroid cancer do not have any symptoms.
View Article and Find Full Text PDFHeart Lung Circ
January 2025
Edwards Lifesciences ANZ, Sydney, NSW, Australia.
Background: Untreated severe heart valve disease (HVD) is associated with premature mortality. Research shows low population awareness of when to seek assessment and low focus on cardiac auscultation by physicians in primary care settings. We studied contemporary public knowledge of HVD and assessment by their general practitioner (GP) in Australia.
View Article and Find Full Text PDFLeuk Res
January 2025
Division of Hematology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. Electronic address:
Clonal isotype switch (CIS) in multiple myeloma (MM) refers to the emergence of new immunoglobulin bands distinct from those present at diagnosis. CIS often appears after high-dose chemotherapy and autologous stem cell transplantation (ASCT), reflecting post-transplant immune recovery. However, its prognostic significance remains unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!